IGM Biosciences (IGMS) to Release Quarterly Earnings on Wednesday

IGM Biosciences (NASDAQ:IGMS) is projected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 14th. Analysts expect IGM Biosciences to post earnings of ($0.41) per share and revenue of $4.25 million for the quarter.

IGM Biosciences (NASDAQ:IGMS) last released its earnings results on Thursday, March 6th. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.13. IGM Biosciences had a negative net margin of 7,534.03% and a negative return on equity of 155.42%. The firm had revenue of $0.41 million during the quarter, compared to analyst estimates of $0.39 million. On average, analysts expect IGM Biosciences to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

IGM Biosciences Stock Performance

IGM Biosciences stock opened at $1.19 on Tuesday. IGM Biosciences has a 1 year low of $0.92 and a 1 year high of $22.50. The firm’s 50-day moving average is $1.24 and its 200-day moving average is $4.56. The company has a market cap of $71.13 million, a P/E ratio of -0.33 and a beta of 0.61.

Hedge Funds Weigh In On IGM Biosciences

A hedge fund recently bought a new stake in IGM Biosciences stock. Invesco Ltd. bought a new stake in shares of IGM Biosciences, Inc. (NASDAQ:IGMS) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 36,127 shares of the company’s stock, valued at approximately $42,000. Invesco Ltd. owned approximately 0.06% of IGM Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 42.79% of the company’s stock.

Wall Street Analyst Weigh In

Separately, JPMorgan Chase & Co. upgraded IGM Biosciences from an “underweight” rating to a “neutral” rating in a research note on Monday, January 13th. One research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $5.50.

About IGM Biosciences

IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.